ESR1 and breast cancer: The splice variants of ERα have previously demonstrated synergistic deleterious effects in laryngeal cancer cell lines21, however the crosstalk between the different pathways is much more intricate, as the loss of the expression of ERα66 seems to confer the most aggressive phenotype, similar to that seen in breast cancer.